Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186234 | 0.94 | KDR (0.71) | KDRBRAFCITMAP3K7RIPK2 | |
| SCHEMBL7012450 | 0.92 | KDR (0.59) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6105755 | 0.92 | KDR (0.59) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6103204 | 0.86 | KDR (0.58) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6105084 | 0.86 | KDR (0.58) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6105513 | 0.84 | KDR (0.53) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1115273 | 0.84 | KDR (0.57) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6103548 | 0.84 | KDR (0.57) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL201280 | 0.84 | KDR (0.57) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7020478 | 0.81 | KDR (0.54) | KDRTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100074909-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2010-03-25 | — | — | US | claimed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | claimed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| EP-3170824-B1 | A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR | AMGEN INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20190185572-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170247459-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050118643-A1 | Specific binding agents to hepatocyte growth factor | AMGEN INC | 2005-06-02 | — | — | US | disclosed |
| WO-2005017107-A2 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885TUBB4A 3130/4885TUBB 3381/4885 |
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885TUBB4A 66/4885TUBB 44/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885TUBB4A 3130/4885TUBB 3381/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885TUBB4A 3130/4885TUBB 3381/4885 |
| US-20100074909-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885TUBB4A 66/4885TUBB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.